Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

trials in solid tumor indications, including a Phase III clinical trial in combination with gemcitabine in locally advanced and metastatic pancreatic cancer. Lorus has reported that the overall survival data in this Phase III study did not reach statistical significance, although exploratory analysis yielded promising results in specific patient populations including in patients with ECOG performance status of 0 or 1.

In April 2008, Lorus' subsidiary GeneSense Technologies entered into an exclusive multinational license agreement for Virulizin(R) with Zor Pharmaceuticals LLC to further develop and commercialize Virulizin(R) for advanced pancreatic cancer and other therapy areas in North and South America, Europe, and Israel.

Virulizin(R) study leads to new drug candidate IL-17E

The article entitled "Virulizin(R) induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors" was published online in the journal Cancer Immunology Immunotherapy and is available through PubMed (http://www.ncbi.nlm.nih.gov/PubMed/).

The study showed that Virulizin(R) treatment stimulates the immune system to produce the cytokine IL-17E, which in turn triggers an anticancer effect through activation and tumor recruitment of eosinophils. This novel aspect of the anticancer mechanism of action for Virulizin(R) adds to previous studies showing that Virulizin(R) activates other cells of the immune system, including macrophages and Natural Killer (NK) cells.

A key finding of this report was that IL-17E itself had significant anticancer activity when used in mouse models of human cancers. Preliminary studies have revealed that IL-17E has potent activity against several human tumor types, including colon cancer, melanoma, and pancreatic cancer, with low toxicity. Lorus has patent applications pending in major markets, including Canada, Europe and the United St
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 ... based on the products of cells grown under ... entered into an international license agreement with Suneva ... proprietary multipotent cell conditioned media (CCM). ... existing license between Histogen and Suneva Medical, through ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research ... ALQA). Alliqua is an emerging biomedical company acquiring, ... the wound care market. , Free report download: ... was restructured with a seasoned management team and ... become a leading provider of wound care products. ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader ... as the new Director of Product Strategy. In this ... as well as iLab sub-teams to guide in the ... to ensure that iLab provides the maximum possible benefit ... user-friendly, and high-impact solution in the world. , ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ... to challenges related to patient safety, clinical outcomes, ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Dr. William Yasnoff agreed that $30 million is ... the adoption of electronic health records, but not too small ... idea. , ,Yasnoff, founder of the eHealth Trust Initiative, continues ... or bank, for all electronic health records. He views a ...
... and we have to do something major about its inefficiencies. ... (27 percent), industry (25 percent), and buildings (48 percent). The ... statistics published in 2003. , ,I was told ... also said the only way for the United States to ...
... using technology efficiently? Protecting customer information? Upgrading major ... inside your business so that you know that ... in mind? , ,Businesses are becoming increasingly dependent ... manage risks, or even just to operate. But ...
Cached Biology Technology:Yasnoff: Wisconsin should invest in health record bank 2Yasnoff: Wisconsin should invest in health record bank 3Energy conservation might take us farther than renewable fuels 2Energy conservation might take us farther than renewable fuels 3Energy conservation might take us farther than renewable fuels 4Energy conservation might take us farther than renewable fuels 5Energy conservation might take us farther than renewable fuels 6Are your business and technology goals aligned? 2Are your business and technology goals aligned? 3
(Date:4/15/2014)... dental researchers have found a less invasive way ... mouth to study how the mouth,s natural defenses ... some specialized immune cells (white blood cells known ... in the mouthor reject foreign tissues, such as ... about treating and preventing such health issues as ...
(Date:4/15/2014)... Academy of Arts and Sciences (KNAW) has announced the ... awarded prestigious Heineken Prizes (one million US dollars prize ... for their great merits to science. , This year ... awarded to the Austrian-American chemist Erwin Chargaff in 1964. ... Prizes to the following laureates: , Christopher ...
(Date:4/15/2014)... parasites of cuttlefish, squid and octopus has uncovered ... shown how they may help in investigating populations ... has described 10 new parasite species− dicyemid mesozoans ... (cuttlefish, squid and octopus). They are the ... Australian waters. , "Although dicyemid parasites have ...
Breaking Biology News(10 mins):New method isolates immune cells for researchers to study how they ward off oral diseases 2Five scientists awarded prestigious Heineken Prizes 2Bizarre parasite may provide cuttlefish clues 2
... LAKE CITY, May 4, 2009 Women who have babies ... than other women. Now, a new study shows their brothers ... the same genes prolong lifespan and female fertility, and may ... women in your family give birth at older ages, you ...
... Health have identified a gene associated with narcolepsy, a ... bouts of sleep that can strike at any time, ... known role in the immune system, which strongly suggests ... the body,s own tissues, plays an important role in ...
... be more vulnerable than men to the cancer-causing effects ... week at the European Multidisciplinary Conference in Thoracic Oncology ... lung cancer patients who were referred to a cancer ... found women tended to be younger when they developed ...
Cached Biology News:Late motherhood boosts family lifespan 2Late motherhood boosts family lifespan 3Late motherhood boosts family lifespan 4Late motherhood boosts family lifespan 5Genetic study confirms the immune system's role in narcolepsy 2Genetic study confirms the immune system's role in narcolepsy 3